Onset of Action of Selected Second-Generation Antipsychotics (Pines)-A Systematic Review and Meta-Analyses.
Rikke MeyerKenneth SkovInderjeet Kaur DhillonEmilie OlssonNiels Albert GraudalLone BaandrupGesche JürgensPublished in: Biomedicines (2022)
Recommendations for duration of treatment with antipsychotics before considering a switch vary from 2 to 8 weeks, although several studies suggest a rapid onset of action. The objective of this review was to estimate time to onset of action and time to maximum antipsychotic effect of asenapine, olanzapine, quetiapine, and zotepine (pines). We searched bibliographic databases for randomized, placebo-controlled trials in adults with schizophrenia estimating the antipsychotic effect of pines over time. Thirty-five studies including 6331 patients diagnosed with chronic schizophrenia were included. We estimated the standardized mean differences (SMD) of changes in symptom score from baseline to follow-up between intervention and placebo groups across studies using meta-analysis techniques. The summarized effect across all included pines administered as immediate-release formulations showed a statistically significant effect at week 1 (SMD, -0.20 [CI95% -0.28, -0.13]), which increased until week 3 (SMD, -0.42 [CI95% -0.50, -0.34]), after which the effect leveled off (week 6: SMD, -0.53 [CI95% -0.62, -0.44]). The sensitivity analyses of the individual pines confirm this finding, although data sparsity increases variability and limits conclusiveness of these analyses.
Keyphrases
- placebo controlled
- double blind
- systematic review
- meta analyses
- case control
- randomized controlled trial
- phase iii
- end stage renal disease
- clinical trial
- phase ii
- newly diagnosed
- chronic kidney disease
- study protocol
- ejection fraction
- open label
- machine learning
- big data
- radiation therapy
- phase ii study
- preterm birth
- clinical practice
- gestational age